Everything below concerns analytical standard. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
== Career == Langer has been called mother of positive psychology and the "mother of mindfulness." Her work helped to presage mind/body medicine,, which now has "considerable evidence that an array of mind-body therapies can be used as effective adjuncts to conventional medical treatment." She has co-authored experimental research indicating a connection between time perception and wound healing. She has published over 200 articles and academic texts, was published in The New York Times, and discussed her works on Good Morning America. Her studies are required reading in many introductory psychology courses at universities across the United States. Langer has been called a trailblazer who initiated a transformative shift in perspective. Her Harvard colleague, psychologist Daniel Gilbert, stated in the 1989 anthology Unintended Thought, "[Langer] pointed out that social inference is not always a conscious and deliberate act; rather it is often the province of mindless automata." He further noted, "This clarion call was widely appreciated, and if Langer did not quite set the stage for a psychology of unconscious social inference, she at least rented the theatre."
The ciliate Pseudoblepharisma tenue has two bacterial symbionts, one pink, one green. In 2021, both symbionts were confirmed to be photosynthetic: Ca. Thiodictyon intracellulare (Chromatiaceae), a purple sulfur bacterium with a genome just half the size of their closest known relatives; and Chlorella sp. K10, a green alga. There is also a variant of Pseudoblepharisma tenue that only contains chloroplasts from green algae and no endosymbiotic purple bacteria.
Sudanese Sovereignty Council (Arabic: مجلس السيادة السوداني), or Supreme Commission or Commission of Sovereignty, is a presidential council in Sudan that was formed for the first time in 1955. Since then, it has been dissolved and reconstituted more than once. Its most famous councils may refer to:
Sources: en.wikipedia.org
=== Insomnia === Orexin receptor antagonists dose-dependently improve sleep parameters including latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), total sleep time (TST), and sleep quality (SQ). Orexin receptor antagonists are not currently used as first-line treatments for insomnia due to cost and concerns about possible misuse liability.
Beyond its structural effects, intracrine Ang II has been shown to alter cardiac electrical conductivity, increasing the risk of arrhythmias. Intracellular dialysis of Ang II in cardiomyocytes has been observed to reduce junctional conductance and alter calcium signaling, which may contribute to the development of atrial fibrillation and other arrhythmias in conditions such as heart failure. Additionally, the ability of intracrine Ang II to modulate gap junctions and ion channels highlights its potential role in electrical remodeling of the heart. This mechanism may underlie the persistent electrical abnormalities seen in pathological cardiac conditions.
Sheikha Fatima bint Hazza bin Zayed Al Nahyan. Sheikha Salama bint Hazza bin Zayed Al Nahyan. Sheikh Zayed bin Hazza bin Zayed Al Nahyan (born 1995). He has one son. Sheikh Hazza bin Zayed Al Nahyan (born 2026). Sheikha Meera bint Hazza bin Zayed Al Nahyan. She married Sheikh Zayed bin Mansour bin Zayed Al Nahyan on May 5, 2022. Sheikh Mohammed bin Hazza bin Zayed Al Nahyan (born 2002).
== Medicine == Researchers in 2011 discovered the ability of graphene to accelerate the osteogenic differentiation of human mesenchymal stem cells without the use of biochemical inducers. In 2015 researchers used graphene to create biosensors with epitaxial graphene on silicon carbide. The sensors bind to 8-hydroxydeoxyguanosine (8-OHdG) and is capable of selective binding with antibodies. The presence of 8-OHdG in blood, urine and saliva is commonly associated with DNA damage. Elevated levels of 8-OHdG have been linked to increased risk of several cancers. By the next year, a commercial version of a graphene biosensor was being used by biology researchers as a protein binding sensor platform. In 2016 researchers revealed that uncoated graphene can be used as neuro-interface electrode without altering or damaging properties such as signal strength or formation of scar tissue. Graphene electrodes in the body are significantly more stable than electrodes of tungsten or silicon because of properties such as flexibility, bio-compatibility and conductivity.
Sources: en.wikipedia.org
GST proteins are globular proteins with an N-terminal mixed helical and beta-strand domain and an all-helical C-terminal domain. The porcine pi-class enzyme pGTSP1-1 was the first GST to have its structure determined, and it is representative of other members of the cytosolic GST superfamily, which contain a thioredoxin-like N-terminal domain as well as a C-terminal domain consisting of alpha helices. Mammalian cytosolic GSTs are dimeric, with both subunits being from the same class of GSTs, although not necessarily identical. The monomers are approximately 25 kDa in size. They are active over a wide variety of substrates with considerable overlap. The following table lists all GST enzymes of each class known to exist in Homo sapiens, as found in the UniProtKB/Swiss-Prot database.
==== MeSH E05.196.712 – photometry ==== MeSH E05.196.712.224 – densitometry MeSH E05.196.712.224.187 – absorptiometry, photon MeSH E05.196.712.224.375 – densitometry, x-ray MeSH E05.196.712.516 – luminescent measurements MeSH E05.196.712.516.200 – chemiluminescent measurements MeSH E05.196.712.516.600 – fluorometry MeSH E05.196.712.516.600.240 – cytophotometry MeSH E05.196.712.516.600.240.350 – flow cytometry MeSH E05.196.712.516.600.240.400 – image cytometry MeSH E05.196.712.516.600.240.400.500 – laser scanning cytometry MeSH E05.196.712.516.600.390 – fluorescence polarization MeSH E05.196.712.516.600.390.350 – fluorescence polarization immunoassay MeSH E05.196.712.516.600.393 – fluorescence recovery after photobleaching MeSH E05.196.712.516.600.410 – fluorophotometry MeSH E05.196.712.516.600.676 – spectrometry, fluorescence MeSH E05.196.712.516.600.676.500 – fluorescence resonance energy transfer MeSH E05.196.712.650 – nephelometry and turbidimetry MeSH E05.196.712.726 – spectrophotometry MeSH E05.196.712.726.300 – microspectrophotometry MeSH E05.196.712.726.551 – spectrophotometry, atomic MeSH E05.196.712.726.676 – spectrophotometry, infrared MeSH E05.196.712.726.676.700 – spectroscopy, fourier transform infrared MeSH E05.196.712.726.802 – spectrophotometry, ultraviolet
== Biosynthesis == 2,5-DKPs are synthesized by a variety of organisms including humans. In general, they arise by the action of a tRNA-dependent cyclodipeptide synthases, a type of enzyme responsible for creating a cyclic amide linkage between two peptides. The enzymes cyclodipeptide oxidase and S-adenosyl-methionine-dependent O/N methyltransferases act in tandem to chemically modify cyclic dipeptides.
Neutrophil collagenase, also known as matrix metalloproteinase-8 (MMP-8) or PMNL collagenase (MNL-CL), is a collagen cleaving enzyme which is present in the connective tissue of most mammals. In humans, the MMP-8 protein is encoded by the MMP8 gene. The gene is part of a cluster of MMP genes which localize to chromosome 11q22.3. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. However, the enzyme encoded by this gene is stored in secondary granules within neutrophils and is activated by autolytic cleavage.
Second-harmonic imaging microscopy (SHIM) is based on a nonlinear optical effect known as second-harmonic generation (SHG). SHIM has been established as a viable microscope imaging contrast mechanism for visualization of cell and tissue structure and function. A second-harmonic microscope obtains contrasts from variations in a specimen's ability to generate second-harmonic light from the incident light while a conventional optical microscope obtains its contrast by detecting variations in optical density, path length, or refractive index of the specimen. SHG requires intense laser light passing through a material with a noncentrosymmetric molecular structure, either inherent or induced externally, for example by an electric field. Second-harmonic light emerging from an SHG material is exactly half the wavelength (frequency doubled) of the light entering the material. While two-photon-excited fluorescence (TPEF) is also a two photon process, TPEF loses some energy during the relaxation of the excited state, while SHG is energy conserving. Typically, an inorganic crystal is used to produce SHG light such as lithium niobate (LiNbO3), potassium titanyl phosphate (KTP = KTiOPO4), or lithium triborate (LBO = LiB3O5). Though SHG requires a material to have specific molecular orientation in order for the incident light to be frequency doubled, some biological materials can be highly polarizable, and assemble into fairly ordered, large noncentrosymmetric structures.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.